In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

[1]  N. Kröger,et al.  Anti-Thymocyte-Globulin as part of the preparative regimen prevents graft failure and severe Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors , 2001, Annals of Hematology.

[2]  C. Schmoor,et al.  Allogeneic bone marrow transplantation from unrelated donors using in vivo anti‐T‐cell globulin , 2000, British journal of haematology.

[3]  M. Remberger,et al.  Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation , 1999, Bone Marrow Transplantation.

[4]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[5]  M. Martelli,et al.  Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Kröger,et al.  Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow , 1999, Bone Marrow Transplantation.

[7]  A. Zander,et al.  Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients , 1999, Bone Marrow Transplantation.

[8]  M. Horowitz,et al.  Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. , 1998, Blood.

[9]  N. Young,et al.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect , 1998, Bone Marrow Transplantation.

[10]  S. Mackinnon,et al.  T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. , 1998, Blood.

[11]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[12]  M. Kook.  T-cell Depleted Bone Marrow Transplantation , 1995 .

[13]  H. Heimpel,et al.  In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. , 1995, Bone marrow transplantation.

[14]  S. Steinberg,et al.  T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse , 1995, British journal of haematology.

[15]  H. Deeg,et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.

[16]  H. Nieuwenhuis,et al.  Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft [see comments] , 1994 .

[17]  H. Nieuwenhuis,et al.  Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. , 1994, Blood.

[18]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[19]  B. Shank,et al.  T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. , 1992, Blood.

[20]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[21]  S. Feig,et al.  Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[22]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[23]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Deeg,et al.  Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. , 1988, Bone marrow transplantation.

[25]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[26]  S. Feig,et al.  Graft failure and leukemia relapse following T lymphocyte-depleted bone marrow transplants: effect of intensification of immunosuppressive conditioning. , 1987, Transplantation proceedings.

[27]  H. Heimpel,et al.  Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantation , 1986, British journal of haematology.

[28]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. , 1986, Bone marrow transplantation.